|

Radical Surgery for Peritoneal Mesothelioma Boosts Survival

ByAlex Strauss
radical surgery for peritoneal mesothelioma

Patients who have radical surgery for peritoneal mesothelioma live longer than those who have non-surgical treatments. 

That is the conclusion of a team of Virginia researchers. The study is based on peritoneal mesothelioma cases in the National Cancer Database. It spans more than a decade and includes over 2,000 patients. 

Not everyone is a candidate for radical surgery for peritoneal mesothelioma. But the research shows that those who have surgery live an average of five times longer than those who do not. 

Surgical Treatment of Peritoneal Mesothelioma

Peritoneal mesothelioma is sometimes called diffuse malignant peritoneal mesothelioma. It is an aggressive cancer in the abdomen. It grows on the membrane around organs. Because mesothelioma tumors lie so close to these organs, it is easy for the cancer to spread. 

Radical surgery for peritoneal mesothelioma involves removing the diseased membrane. Surgeons may also have to remove tumors from other parts of the abdomen. 

By the time patients receive a mesothelioma diagnosis, it is sometimes too late for radical surgery. If the cancer is too widespread, or if the patient is not in good enough health, patients may have chemotherapy instead. 

But the new study finds that survival after chemotherapy is not nearly as high as it is after radical surgery. A combination of radical surgery for peritoneal mesothelioma and intraperitoneal chemotherapy (HIPEC) produced the best odds of survival. 

Evaluating Radical Surgery for Peritoneal Mesothelioma

The new study uses data from the National Cancer Database. It focused on 2,062 peritoneal mesothelioma patients diagnosed between 2003 and 2014. 

More than half (51%) of the patients did not have surgery. Most of these patients just had chemotherapy with Alimta. This group of patients had a median overall survival of 7.1 months.  

Seven-hundred-and-one patients (34%) had aggressive treatment with radical surgery for peritoneal mesothelioma. Overall survival in this group was 38.4 months. Among those who also had a rinse of heated chemotherapy during surgery (HIPEC), overall survival jumped to 41.8 months. 

“Patients selected for and treated with radical surgery had significantly better overall survival compared with those receiving nonsurgical treatment,” writes Lana Bijelic. Dr. Bijelic is medical director of surgical oncology at Inova Fairfax Hospital. She is first author on the paper in the Annals of Surgical Oncology. 

Dr. Bijelic and her colleagues recommend that all newly-diagnosed patients be evaluated for radical surgery for peritoneal mesothelioma. 

According to the CDC, more than 45,000 people died of all forms of mesothelioma between 1999 and 2015. Peritoneal mesothelioma accounts for about a fifth of those cases. It takes an average of 20 to 40 years for peritoneal mesothelioma to develop after asbestos exposure. 

Sources:

Bijelic, L, et al, “Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database”, January 31, 2020, Annals of Surgical Oncology, Epub ahead of print, https://link.springer.com/article/10.1245%2Fs10434-019-08138-5

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

Value of Mesothelioma Surgery Challenged for Healthy Patients
| |

Value of Mesothelioma Surgery Challenged for Healthy Patients

ByAlex Strauss

New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…